{"product_id":"vigl-vrio-analysis","title":"Vigil Neuroscience, Inc. (VIGL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the sustainable competitive advantage of Vigil Neuroscience, Inc. (VIGL) hinges on a rigorous VRIO analysis. Discover immediately whether its core resources are truly Valuable, Rare, Inimitable, and Organized to exploit - the four pillars determining long-term market success. Dive into the findings below to see the strategic implications for Vigil Neuroscience, Inc. (VIGL)'s future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 1. VG-3927 Clinical Program (Oral TREM2 Agonist for AD)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a potential game-changer for Alzheimer’s disease (AD) that has just moved under a major pharma umbrella. The core takeaway here is that VG-3927 has cleared a significant hurdle with positive Phase 1 data, but its sustained advantage depends entirely on what happens next in Phase 2, which is now Sanofi’s problem to manage.\u003c\/p\u003e\n\n\u003ch3\u003eValue: First-in-Class Oral Potential in a Massive Unmet Need\u003c\/h3\u003e\n\u003cp\u003eThe value proposition for VG-3927 is huge: it’s an oral, once-daily small molecule targeting TREM2, a mechanism distinct from the current amyloid-clearing antibodies. This convenience factor alone could capture significant market share in the massive AD space, which affects about seven million people in the US. The Phase 1 trial, which included 115 participants, proved the concept works in humans. Specifically, the data showed a robust and dose-dependent reduction of soluble TREM2 (sTREM2) in the cerebrospinal fluid (CSF) of up to approximately \u003cstrong\u003e50%\u003c\/strong\u003e, confirming strong target engagement. This is defintely a strong signal for a first-in-class oral therapy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOral, once-daily dosing offers a convenience edge.\u003c\/li\u003e\n\u003cli\u003ePhase 1 showed strong target engagement.\u003c\/li\u003e\n\u003cli\u003ePlanned Phase 2 trial initiation is set for Q3 \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Small Molecule Agonism is Scarce\u003c\/h3\u003e\n\u003cp\u003eWhile the TREM2 target itself isn't a secret, developing a successful small molecule agonist that hits the mark is proving difficult. You have to look no further than the fact that Denali Therapeutics and Takeda discontinued their partnered TREM2 candidate following Phase 1 data. This failure highlights the technical difficulty. Vigil, prior to the acquisition, claimed VG-3927 was the first and only Phase 2-ready oral, once-daily small molecule TREM2 agonist. That specific profile - oral, small molecule, and Phase 2-ready - is rare right now, even if the general mechanism is known.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the competitive landscape context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset Type\u003c\/th\u003e\n\u003cth\u003eMechanism\u003c\/th\u003e\n\u003cth\u003eStatus\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVG-3927\u003c\/td\u003e\n\u003ctd\u003eOral Small Molecule TREM2 Agonist\u003c\/td\u003e\n\u003ctd\u003ePhase 2 ready (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitor X\/Y\u003c\/td\u003e\n\u003ctd\u003eTREM2-targeting drug candidate\u003c\/td\u003e\n\u003ctd\u003eDiscontinued post-Phase 1 (2024\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability: Molecule vs. Mechanism\u003c\/h3\u003e\n\u003cp\u003eThe general mechanism - activating TREM2 to enhance microglial neuroprotection - is public knowledge, which means the idea is not inimitable. However, the specific molecule, VG-3927, and its unique Phase 1 data package are not easily copied. Synthesizing a novel small molecule with the precise pharmacokinetic (PK) and pharmacodynamic (PD) profile that achieved that \u003cstrong\u003e50%\u003c\/strong\u003e sTREM2 reduction in CSF takes significant time and specialized chemistry. What this estimate hides is the proprietary knowledge embedded in the molecule’s structure and the specific dosing regimen (\u003cstrong\u003e25mg\u003c\/strong\u003e QD) selected.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Sanofi’s Global Engine Now Drives Development\u003c\/h3\u003e\n\u003cp\u003eThe company’s organization has fundamentally changed. Vigil was structured to get the asset to Phase 2, which it achieved, reporting a net loss of \u003cstrong\u003e$22.4 million\u003c\/strong\u003e in Q1 \u003cstrong\u003e2025\u003c\/strong\u003e while holding \u003cstrong\u003e$87.1 million\u003c\/strong\u003e in cash. Now, Sanofi is acquiring the entire entity for approximately \u003cstrong\u003e$470 million\u003c\/strong\u003e in cash (plus a \u003cstrong\u003e$2\u003c\/strong\u003e per share CVR). Sanofi’s global infrastructure, deep neurology expertise, and immunology capabilities provide a massive organizational advantage for scaling development and eventual commercialization. The asset is now organized under a top-tier pharma structure, which is a huge positive for execution risk.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Hinges on Phase 2\u003c\/h3\u003e\n\u003cp\u003eRight now, the advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. The positive Phase 1 data and the Sanofi backing grant a temporary lead in the oral TREM2 space. However, this advantage is entirely contingent on the upcoming Phase 2 trial results, which are still pending. If Phase 2 data confirms clinical efficacy in AD patients, the advantage could shift toward sustained. If it fails, the advantage evaporates instantly. The market is pricing in the potential for a sustained advantage, evidenced by the \u003cstrong\u003e$8\u003c\/strong\u003e per share cash offer plus the CVR.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, incorporating the expected Q3 Sanofi close timeline.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 2. Iluzanebart Clinical Program (Monoclonal Antibody for ALSP)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe asset offered potential treatment for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP), a rare, fatal neurodegenerative disease affecting an estimated \u003cstrong\u003e19,000 people in the United States\u003c\/strong\u003e. The Phase 2 IGNITE trial evaluated iluzanebart in \u003cstrong\u003e20 patients\u003c\/strong\u003e with a confirmed \u003cstrong\u003eCSF1R gene mutation\u003c\/strong\u003e. Patients received intravenous infusions at either \u003cstrong\u003e20 mg\/kg or 40 mg\/kg\u003c\/strong\u003e approximately every \u003cstrong\u003efour weeks for one year\u003c\/strong\u003e. The final analysis, reported in \u003cstrong\u003eJune 2025\u003c\/strong\u003e, indicated \u003cstrong\u003eno beneficial effects on biomarker or clinical efficacy endpoints\u003c\/strong\u003e with treatment. The company had previously planned to pursue an accelerated approval pathway based on \u003cstrong\u003e12-month\u003c\/strong\u003e data.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eALSP Estimated US Prevalence\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19,000\u003c\/strong\u003e people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGNITE Trial Enrollment (Actual)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Treatment Duration (Core Study)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1 year\u003c\/strong\u003e (52 weeks)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Cohorts\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20 mg\/kg\u003c\/strong\u003e and \u003cstrong\u003e40 mg\/kg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGNITE Final Analysis Planned Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ2 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Outcome (June 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo beneficial effects\u003c\/strong\u003e on biomarker or clinical efficacy endpoints\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe target indication, ALSP, is a rare, inherited, autosomal dominant neurological disease caused by a mutation to the \u003cstrong\u003eCSF1R gene\u003c\/strong\u003e. The ILLUMINATE natural history study was the \u003cstrong\u003efirst\u003c\/strong\u003e such study in ALSP. The regulatory path considered an accelerated approval pathway based on \u003cstrong\u003e12-month\u003c\/strong\u003e data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific monoclonal antibody, iluzanebart (VGL101), and the accumulated data set from the \u003cstrong\u003ePhase 2 IGNITE trial\u003c\/strong\u003e, which involved \u003cstrong\u003e20 patients\u003c\/strong\u003e, were unique to the company’s development efforts.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization successfully navigated the completion of patient enrollment for the IGNITE trial, exceeding the initial target of \u003cstrong\u003e15 patients\u003c\/strong\u003e. The company reported \u003cstrong\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/strong\u003e of \u003cstrong\u003e$16.5 million\u003c\/strong\u003e for the first quarter ended \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e. Following the final analysis in \u003cstrong\u003eJune 2025\u003c\/strong\u003e, the \u003cstrong\u003ePhase 2 long-term extension study\u003c\/strong\u003e was \u003cstrong\u003ediscontinued\u003c\/strong\u003e in accordance with previously disclosed processes.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIGNITE Trial Enrollment Target: \u003cstrong\u003e15\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eIGNITE Trial Enrollment Actual: \u003cstrong\u003e20\u003c\/strong\u003e patients\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Net Loss from Operations: \u003cstrong\u003e$22.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities as of March 31, 2025: \u003cstrong\u003e$87.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is \u003cstrong\u003eEroded\/Temporary\u003c\/strong\u003e. The program's potential competitive advantage was contingent upon achieving positive efficacy data to support an accelerated approval pathway. The \u003cstrong\u003eJune 2025\u003c\/strong\u003e update confirmed \u003cstrong\u003eno beneficial effects\u003c\/strong\u003e on efficacy endpoints, leading to the discontinuation of the long-term extension study. Furthermore, the definitive agreement for acquisition by Sanofi specified that Sanofi would \u003cstrong\u003enot\u003c\/strong\u003e be purchasing Iluzanebart (VGL101).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 3. Proprietary TREM2 Scientific Platform\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eDeep, focused expertise in microglial biology and the TREM2 pathway, which underpins both lead candidates and future pipeline exploration. The platform supports two distinct modalities targeting TREM2: an antibody (iluzanebart) and a small molecule (VG-3927). The company's commitment is reflected in its R\u0026amp;D investment, with Research and Development (R\u0026amp;D) Expenses reported as \u003cstrong\u003e$13.8 million\u003c\/strong\u003e in Q3 2024 and \u003cstrong\u003e$16.5 million\u003c\/strong\u003e in Q1 2025.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. Other firms target microglia, but Vigil’s specific focus and validated approach are distinct, positioning them as the 'world's first microglia-focused therapeutics company.' The small molecule agonist, VG-3927, demonstrated a dose-dependent reduction in soluble TREM2 (sTREM2) of up to \u003cstrong\u003e50%\u003c\/strong\u003e in cerebrospinal fluid (CSF) in Phase 1 trials. The company has between \u003cstrong\u003e51-200 Employees\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh. This deep, specialized scientific knowledge takes years of focused research to build. The platform's development has resulted in two clinical candidates: iluzanebart for ALSP and VG-3927 for Alzheimer's Disease (AD). The successful Phase 1 data for VG-3927 showed a CSF to unbound plasma ratio of \u003cstrong\u003e0.91\u003c\/strong\u003e, indicating high CNS penetrance. The company secured a \u003cstrong\u003e$40 million\u003c\/strong\u003e strategic investment from Sanofi in June 2024.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe team’s entire R\u0026amp;D strategy is built around this platform, showing strong alignment. This focus was validated by the acquisition of the company by Sanofi for an equity value of approximately \u003cstrong\u003e€405 million\u003c\/strong\u003e (on a fully diluted basis), with shareholders receiving \u003cstrong\u003e€6.91\u003c\/strong\u003e per share in cash at closing, plus a contingent value right (CVR) of \u003cstrong\u003e€1.73\u003c\/strong\u003e per share contingent on VG-3927's first commercial sale. The company expected its cash position of \u003cstrong\u003e$111.3 million\u003c\/strong\u003e as of September 30, 2024, to fund operations into \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Deep scientific expertise is difficult for competitors to replicate quickly. The platform's dual-modality approach offers differentiation, especially as VG-3927 does not bind to sTREM2, which can act as a sink for antibodies. The potential addressable market for ALSP was expanded by new prevalence estimates of approximately \u003cstrong\u003e19,000\u003c\/strong\u003e cases in the U.S. and \u003cstrong\u003e29,000\u003c\/strong\u003e in the EU\/UK combined.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eIluzanebart (ALSP)\u003c\/th\u003e\n\u003cth\u003eVG-3927 (AD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eModality\u003c\/td\u003e\n\u003ctd\u003eFully Human Monoclonal Antibody\u003c\/td\u003e\n\u003ctd\u003eSmall Molecule Agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Clinical Milestone Timing\u003c\/td\u003e\n\u003ctd\u003ePhase 2 IGNITE Final Analysis in Q2 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Trial Initiation in Q3 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Engagement Data\u003c\/td\u003e\n\u003ctd\u003eN\/A (Phase 2 ongoing)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e50%\u003c\/strong\u003e sTREM2 reduction in CSF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 4. ALSP Natural History Data Set (ILLUMINATE Study)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ILLUMINATE study generated a rich, proprietary dataset essential for understanding Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) disease progression and informing regulatory strategy. Key data points include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eData Type\u003c\/th\u003e\n\u003cth\u003eMetric\/Finding\u003c\/th\u003e\n\u003cth\u003eContext\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Target\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e50\u003c\/strong\u003e enrollees\u003c\/td\u003e\n\u003ctd\u003eProspective, multicenter Natural History Study (NHS)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment Status (as of Sept 2023)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e41\u003c\/strong\u003e enrollees with confirmed CSF1R mutation\u003c\/td\u003e\n\u003ctd\u003eIncluded \u003cstrong\u003e23\u003c\/strong\u003e symptomatic and \u003cstrong\u003e18\u003c\/strong\u003e prodromal participants\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFollow-up Duration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e24 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eClinical assessments and MRI collected every 6 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurofilament Light Chain (NfL)\u003c\/td\u003e\n\u003ctd\u003eLevels \u003cstrong\u003eelevated multifold\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSymptomatic participants vs prodromal and healthy individuals (CSF and serum)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCognitive Endpoint Correlation\u003c\/td\u003e\n\u003ctd\u003eStatistically significant correlation\u003c\/td\u003e\n\u003ctd\u003eIncreased ventricular volume correlated with \u003cstrong\u003elower MoCA scores\u003c\/strong\u003e in symptomatic patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Such detailed, longitudinal data for a rare disease like ALSP is scarce, as limited natural history data was previously available to inform therapeutic development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The dataset cannot be recreated without years of patient recruitment and study execution, which is challenging given the rarity of ALSP. The study design involved prospective, multicenter follow-up.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company demonstrated operational capability in rare disease research by executing this prospective, multicenter NHS. Key organizational milestones include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eStudy designed by patients, advocates, and physicians.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eEnrollment of up to \u003cstrong\u003e50\u003c\/strong\u003e participants planned.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCollection of clinical assessments, MRI, and fluid biomarkers (CSF\/blood) at specific visits over the \u003cstrong\u003e24-month\u003c\/strong\u003e follow-up period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This data set represents a sunk cost asset providing critical insights on MRI measures and NfL levels as sensitive markers of ALSP pathophysiology, which competitors cannot easily match.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 5. Sanofi Acquisition Agreement Structure\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe agreement provides an immediate cash infusion of \u003cstrong\u003e$8.00\u003c\/strong\u003e per share upfront. This upfront payment represents an equity value of approximately \u003cstrong\u003e$470 million\u003c\/strong\u003e on a fully diluted basis at the time of the agreement. Shareholders also received a non-transferrable contingent value right (CVR) per share, entitling the holder to a deferred cash payment of \u003cstrong\u003e$2.00\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003cth\u003eBasis\/Condition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Payment Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash at Closing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Upfront Equity Value\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$470 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFully Diluted Basis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Value Right (CVR) Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDeferred Cash Payment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Potential Equity Value\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e$600 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFully Diluted Basis (Upfront + CVR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Strategic Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 2024 Investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe definitive agreement for acquisition by a major pharmaceutical company like Sanofi is a rare event for a company of Vigil Neuroscience's size.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe specific negotiated terms of the merger agreement are unique to Vigil Neuroscience and Sanofi.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe management team successfully negotiated and secured the definitive agreement, demonstrating deal-making acumen.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe transaction included an upfront payment of \u003cstrong\u003e$8.00\u003c\/strong\u003e per share in cash at closing.\u003c\/li\u003e\n\u003cli\u003eThe CVR entitles the holder to an additional \u003cstrong\u003e$2.00\u003c\/strong\u003e per share in cash following the first commercial sale of VG-3927 if achieved within a specific period.\u003c\/li\u003e\n\u003cli\u003eSanofi had previously made a \u003cstrong\u003e$40 million\u003c\/strong\u003e strategic investment in Vigil in June 2024.\u003c\/li\u003e\n\u003cli\u003eThe transaction was expected to close in the third quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eVGL101, Vigil's second clinical program, was explicitly excluded from the acquisition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is considered temporary. The immediate cash realization of \u003cstrong\u003e$470 million\u003c\/strong\u003e (equity value) is secured, but the potential upside of \u003cstrong\u003e$2.00\u003c\/strong\u003e per share via the CVR is contingent on the future commercial performance of VG-3927.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 6. Cash Position and Financial Runway\n\u003c\/h2\u003e\n\u003cp\u003e\nValue:\n\u003c\/p\u003e\n\u003cp\u003e\nCash, cash equivalents, and marketable securities totaled \u003cstrong\u003e$87.1 million\u003c\/strong\u003e as of March 31, 2025. This balance provides a projected operational runway extending into \u003cstrong\u003e2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity:\n\u003c\/p\u003e\n\u003cp\u003e\nModerate. The liquidity position of \u003cstrong\u003e$87.1 million\u003c\/strong\u003e offers stability compared to many clinical-stage biotechs that face liquidity constraints.\n\u003c\/p\u003e\n\u003cp\u003e\nImitability:\n\u003c\/p\u003e\n\u003cp\u003e\nLow. The specific balance sheet amount is unique to the company at this time, although capital raising is a capability available to competitors.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization:\n\u003c\/p\u003e\n\u003cp\u003e\nThe company managed its burn rate to secure the runway into \u003cstrong\u003e2026\u003c\/strong\u003e, despite the net loss from operations increasing to \u003cstrong\u003e$22.4 million\u003c\/strong\u003e in Q1 2025.\n\u003c\/p\u003e\n\u003cp\u003e\nThe following table details key financial metrics for the first quarter:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (USD)\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 (as of Mar 31)\u003c\/td\u003e\n\u003ctd\u003eQ1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$87.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss from Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development (R\u0026amp;D) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative (G\u0026amp;A) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nFurther detail on operational expenses and cash movement:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss from operations for Q1 2025 was \u003cstrong\u003e$22.4 million\u003c\/strong\u003e, an increase from \u003cstrong\u003e$19.9 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q1 2025 were \u003cstrong\u003e$16.5 million\u003c\/strong\u003e, up from \u003cstrong\u003e$14.3 million\u003c\/strong\u003e in Q1 2024, driven by VG-3927 preclinical\/manufacturing and headcount.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expenses for Q1 2025 were \u003cstrong\u003e$7.0 million\u003c\/strong\u003e, consistent with \u003cstrong\u003e$7.1 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities decreased from \u003cstrong\u003e$97.8 million\u003c\/strong\u003e as of December 31, 2024, to \u003cstrong\u003e$87.1 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage:\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. The current liquidity provides a finite runway that depletes with ongoing Research \u0026amp; Development spend, making the advantage temporary until a significant value inflection point is reached.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 7. Intellectual Property Estate (TREM2 Agonist Patents)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLegal protection over the composition of matter and use of its core drug candidates, VG-3927 and iluzanebart, securing future market exclusivity.\u003c\/li\u003e\n\u003cli\u003eThe value is partially reflected in the agreement for Sanofi to acquire Vigil for approximately \u003cstrong\u003e$470 million\u003c\/strong\u003e (equity value on a fully diluted basis).\u003c\/li\u003e\n\u003cli\u003eA prior strategic investment from Sanofi was \u003cstrong\u003e$40 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStandard for the industry, but the specific patents covering these novel molecules are unique.\u003c\/li\u003e\n\u003cli\u003eThe portfolio comprises 9 unique patent families.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eModerate. Competitors can design around patents, but the core IP is a barrier.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has successfully filed and maintained the necessary patent portfolio to support its clinical assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSustained (as long as patents are in force). This is the legal foundation of future revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe scale and status of the Intellectual Property Estate are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eCount\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnique Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent Applications Filed (Excluding Design\/PCT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent Grant Rate (from filed applications)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial context related to the pipeline supported by the IP:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSanofi Acquisition Equity Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$470 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSanofi Strategic Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$87.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eInto 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific data points related to the clinical candidates under patent protection:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVG-3927 Phase 1 trial assessed doses up to \u003cstrong\u003e140 mg\u003c\/strong\u003e (SAD) and up to \u003cstrong\u003e50 mg\u003c\/strong\u003e (MAD).\u003c\/li\u003e\n\u003cli\u003eIluzanebart Phase 2 IGNITE trial included cohorts dosed with \u003cstrong\u003e20 mg\/kg\u003c\/strong\u003e or \u003cstrong\u003e40 mg\/kg\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 8. Management Team and Scientific Leadership\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Experienced leadership, including CEO Ivana Magovčević-Liebisch, J.D., Ph.D., whose expertise is deemed complementary to Sanofi’s neurology capabilities.\u003c\/p\u003e\n\u003cp\u003eThe realized value is quantified by the transaction terms:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Equity Value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$470 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Value Right (CVR) Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Equity Value (Fully Diluted)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$600 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO\/Insider Share Support Percentage\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e16.2%\u003c\/strong\u003e of total common shares outstanding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Experienced biotech leadership is sought after but not unique.\u003c\/p\u003e\n\u003cp\u003eSpecific leadership experience metrics include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CEO led the company from inception through IPO in approximately \u003cstrong\u003e18 months\u003c\/strong\u003e during the peak of the COVID-19 pandemic.\u003c\/li\u003e\n\u003cli\u003eThe appointment of the Chief Medical Officer brought over \u003cstrong\u003e30 years\u003c\/strong\u003e of biopharmaceutical industry experience.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. The specific chemistry and history of the team are not easily replicated.\u003c\/p\u003e\n\u003cp\u003eHistorical validation points demonstrating unique team history:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSanofi made a strategic investment of \u003cstrong\u003e$40 million\u003c\/strong\u003e in June 2024, which included the right of first negotiation for VG-3927.\u003c\/li\u003e\n\u003cli\u003eThe CEO executed the in-licensing deal to secure anchor assets for Vigil from Amgen.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The team was effective enough to attract a major acquisition offer from Sanofi, showing external validation of their talent.\u003c\/p\u003e\n\u003cp\u003eOrganizational success reflected in transaction metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Price Premium Over Share Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e250%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Price vs. 2022 IPO Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$8.00\u003c\/strong\u003e vs. \u003cstrong\u003e$14.00\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Founding Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Employees (as of June 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While the team is joining Sanofi, their past ability to execute is a realized historical advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVigil Neuroscience, Inc. (VIGL) - VRIO Analysis: 9. FDA Accelerated Approval Precedent for Iluzanebart\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpecific guidance from the U.S. Food and Drug Administration (FDA) stating it was open to considering the accelerated approval pathway for iluzanebart in ALSP.\u003c\/li\u003e\n\u003cli\u003eThe IGNITE Phase 2 clinical trial evaluates safety and biomarker endpoints, including magnetic resonance imaging (MRI) and neurofilament light chain (NfL).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGaining explicit FDA guidance for an accelerated path is a significant regulatory de-risking event.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThis is a specific regulatory interaction that cannot be copied.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company successfully engaged the FDA following a Type C Meeting to establish this regulatory strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTemporary. The advantage is realized upon successful data submission and approval, but the guidance itself is a one-time win.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey Program and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIluzanebart Trial Enrollment (IGNITE)\u003c\/td\u003e\n\u003ctd\u003eCompleted Patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIluzanebart Trial Enrollment (IGNITE)\u003c\/td\u003e\n\u003ctd\u003eInitially Planned Patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIluzanebart Data Analysis (IGNITE)\u003c\/td\u003e\n\u003ctd\u003ePlanned Reporting Timeline\u003c\/td\u003e\n\u003ctd\u003eSecond Quarter of 2025 (2Q 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALSP Estimated Prevalence (U.S. + EU\/UK)\u003c\/td\u003e\n\u003ctd\u003eTotal Cases\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e48,000\u003c\/strong\u003e (\u003cstrong\u003e19,000\u003c\/strong\u003e U.S. + \u003cstrong\u003e29,000\u003c\/strong\u003e EU\/UK)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Financials\u003c\/td\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 Financials\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$87.1 million\u003c\/strong\u003e (as of March 31, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Investment\u003c\/td\u003e\n\u003ctd\u003eSanofi Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516276367509,"sku":"vigl-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vigl-vrio-analysis.png?v=1740229245","url":"https:\/\/dcf-model.com\/fr\/products\/vigl-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}